Athera initiates Phase I trial with its fully human antibody PC-mAb

Okt 21, 2014

Athera initiates Phase I trial with its fully human antibody PC-mAb
Oct 21, 2014.

STOCKHOLM, SWEDEN – October 21, 2014. Athera Biotechnologies AB, a Karolinska Development
AB portfolio company, today announced that first dosing of healthy volunteers has been done in a
Phase I study of its fully human antibody PC-mAb. This lead product candidate targets the
inflammatory component of cardiovascular disease, where current therapies are considered to be
inadequate.

“We are pleased to have executed our plans in a very timely manner and are looking forward to the results
from this important first clinical trial with our PC-mAb” says Carina Schmidt, CEO of Athera. “This is a key
achievement for the EU FP7 project CARDIMMUN, aiming to generate proof-of-activity data for PC-mAb.”

Athera’s fully human monoclonal antibody PC-mAb is intended for the treatment of patients with
cardiovascular disease, who are at an increased risk of secondary events and death. It is known from previous
published studies that low plasma levels of endogenous antibodies against phosphorylcholine (anti-PC) are
linked to poor prognosis in acute heart attack patients, as well as in patients with peripheral arterial disease
undergoing vein graft surgery. The current Phase I study will include up to 48 healthy volunteers in a single
ascending dose protocol with safety outcome measures and is performed in Uppsala by CTC Clinical Trial
Consultants AB. The development costs for Athera’s lead product candidate are co-financed by the EU FP7
program, within the project CARDIMMUN.